NIPH Clinical Trials Search

JRCT ID: jRCTs042230142

Registered date:18/03/2024

Continuous glucose monitoring for pancreatic cancer patients

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedCases scheduled for pancreatoduodenectomy for resectable pancreatic cancer.
Date of first enrollment22/03/2024
Target sample size20
Countries of recruitment
Study typeInterventional
Intervention(s)Using a continuous glucose monitoring device to monitor glycemic variability throughout the treatment process in cases of pancreatic cancer.


Primary OutcomeThe glycemic variability levels measured during each period of the treatment course for pancreatic cancer patients: Glucose concentrations are measured every 15 minutes for up to 14 days in a single session. Measurements taken for three days or more per session are considered valid. (1) At registration (2) Post neoadjuvant therapy (3) Acute postoperative period (4) Discharge after surgery (5) During postoperative adjuvant therapy (6) After completion of postoperative adjuvant therapy
Secondary Outcome(1) Association between glycemic variability and treatment adherence Presence of preoperative complications, impact on the initiation of NAC (Neoadjuvant Chemotherapy) Adherence to NAC Impact on the start of surgery Postoperative complications, impact on the initiation of adjuvant therapy after surgery Adherence to postoperative adjuvant therapy (2) Relationship between glycemic variability and clinical symptoms (weight changes, nutritional status[Alb, T-chol, Lymphocyte, PNI, NLR, PLR, CONUT)

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum<= 85age old
Include criteria(1) Cases diagnosed with resectable pancreatic cancer. (2) Cases scheduled for pancreatoduodenectomy. (3) The age at the time of consent acquisition is between 18 and 85 years. (4) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is 0 or 1. (5) Meets all the following conditions based on the latest preoperative test values within 30 days before registration: - White blood cell count: >=2,500/uL and <=10,000/uL - Platelet count >=10/*10^4uL - AST (Aspartate Aminotransferase): <=100U/L - ALT (Alanine Aminotransferase): <=100U/L - Total bilirubin: <=2.0 mg/dL (or <=4.0 mg/dL for cases with biliary drainage due to jaundice) - Serum creatinine: <=1.5 mg/dL (6) Written consent for participation in the trial has been obtained from the patient.
Exclude criteria(1) Cases undergoing pancreatic resection other than pancreatoduodenectomy (such as total pancreatectomy,distal pancreatectomy, central pancreatectomy, or local pancreatectomy). (2) Undergoing continuous glucose monitoring for diabetes. (3) Cases deemed unsuitable as subjects for this trial by the attending physician.

Related Information


Public contact
Name Hidemasa Kubo
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777
Telephone +81-55-989-5222
Affiliation Shizuoka Cancer Center
Scientific contact
Name Teiichi Sugiura
Address 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka Shizuoka Japan 411-8777
Telephone +81-55-989-5222
Affiliation Shizuoka Cancer Center